Updated:
SuanFarma
At the Core of a better life. Suanfarma fosters healthier lives in a sustainable world. APIs withCustomized Solutions. We enhance healthcare with...
SuanFarma
At the Core of a better life. Suanfarma fosters healthier lives in a sustainable world. APIs withCustomized Solutions. We enhance healthcare with ourhigh-quality active pharmaceutical ingredients.
General information
Firm type
Private Equity
Year founded
1993
Location
Region
Europe
Country
Spain
City
Madrid
Corporate office
C. de Einstein, 8, 28108 Alcobendas, Madrid, Spain
Additional offices
Mexico City, Mexico · Fair Lawn, NJ, United States · São Paulo, Brazil · Bogotá, Colombia · Navi Mumbai, India · Shanghai, China · Algiers, Algeria · Moscow, Russia · Rovereto, Italy · Lisbon, Portugal
Sector focus
Frequently asked questions
What does SuanFarma do?
SuanFarma operates a dual business: it distributes active pharmaceutical ingredients to more than 400 customers in over 70 countries, and it runs captive manufacturing plants in Portugal and Italy that produce complex APIs and provide contract development and manufacturing services to pharmaceutical companies.
Which markets does SuanFarma serve?
The firm sells into more than 75 countries, supported by 10 area offices in Spain, Mexico, the United States, Brazil, Colombia, India, China, Algeria, Russia, and on-the-ground facilities in Italy and Portugal.
What types of products does SuanFarma specialize in?
Its product lines cover human APIs, veterinary APIs, intermediates, and nutraceutical ingredients. The CDMO arm handles end-to-end development and commercial-scale manufacturing for drug innovators.
Where are SuanFarma's manufacturing facilities located?
The firm operates two primary sites: the Cipan plant in Lisbon, Portugal, and the Rovereto plant in northern Italy. Both combine fermentation and chemical synthesis capabilities and are supported by in-house R&D teams.
Is SuanFarma a manufacturer or a distributor?
It is both. The company runs a global API distribution network while also manufacturing complex small-molecule APIs and intermediates at its own European plants, making it a hybrid trader–drugmaker that controls the supply chain end-to-end.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on private equity firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: